<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e>, including aortic root dilation, dissection, and rupture, is the leading cause of mortality in patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The maximal aortic root diameter at the sinuses of Valsalva is considered the best predictor of adverse cardiovascular outcome </plain></SENT>
<SENT sid="2" pm="."><plain>Although advances in therapy have improved life expectancy, affected individuals continue to suffer <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality </plain></SENT>
<SENT sid="3" pm="."><plain>Recent studies in an FBN1-targeted mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> with <z:e sem="disease" ids="C0003493" disease_type="Disease or Syndrome" abbrv="">aortic disease</z:e> similar to that seen in humans showed that treatment with <z:chebi fb="0" ids="6541">losartan</z:chebi> normalized aortic root growth and aortic wall architecture </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The Pediatric Heart Network designed a randomized clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in subjects with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> receiving atenolol or <z:chebi fb="0" ids="6541">losartan</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Individuals 6 months to 25 years of age with a body surface area-adjusted aortic root z score &gt;3.0 will be eligible for inclusion </plain></SENT>
<SENT sid="6" pm="."><plain>The primary aim is to compare the effect of atenolol therapy with that of <z:chebi fb="0" ids="6541">losartan</z:chebi> therapy on the rate of aortic root growth over 3 years </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary end points include progression of <z:hpo ids='HP_0001659'>aortic regurgitation</z:hpo>; incidence of <z:hpo ids='HP_0002647'>aortic dissection</z:hpo>, aortic root surgery, and <z:hpo ids='HP_0011420'>death</z:hpo>; progression of <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo>; left ventricular size and function; echocardiographically derived measures of central aortic stiffness; skeletal and somatic growth; and incidence of adverse drug reactions </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: This randomized trial should make a substantial contribution to the management of individuals with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and expand our understanding of the mechanisms responsible for the aortic manifestations of this disorder </plain></SENT>
</text></document>